Dow Jones

38 463,45

-0,33%

DAX

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Clarus Therapeutics Holdings Inc (CRXT)
Clarus Therapeutics Holdings Inc (CRXT) Actualités

CRXT

Clarus Therapeutics (CRXT)

Clarus Therapeutics Holdings Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:CRXT

1 2 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
07/03/2023	12h05	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
01/03/2023	13h36	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
01/03/2023	13h23	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
01/03/2023	13h20	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
22/02/2023	22h19	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
18/10/2022	22h05	GlobeNewswire Inc.	Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
14/09/2022	15h52	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
06/09/2022	04h19	GlobeNewswire Inc.	Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
26/08/2022	22h37	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
22/08/2022	18h05	TipRanks	Clarus Therapeutics Holdings (CRXT) was downgraded to a Hold Rating at Needham	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
19/08/2022	12h13	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
18/08/2022	22h05	GlobeNewswire Inc.	Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
28/07/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
06/07/2022	22h00	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
09/06/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
24/05/2022	23h28	Edgar (US Regulatory)	Securities Registration Statement (s-1)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
18/05/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
17/05/2022	12h16	TipRanks	Needham Thinks Clarus Therapeutics Holdings’ Stock is Going to Recover	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
16/05/2022	22h05	GlobeNewswire Inc.	Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
12/05/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
10/05/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
09/05/2022	22h07	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
09/05/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
28/04/2022	15h05	GlobeNewswire Inc.	Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
27/04/2022	22h11	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
27/04/2022	19h43	GlobeNewswire Inc.	Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
27/04/2022	12h07	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
25/04/2022	15h20	GlobeNewswire Inc.	Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
25/04/2022	12h52	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc
22/04/2022	12h15	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:CRXT	Clarus Therapeutics Holdings Inc